A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

The research team led by Associate Professor Lin-Lin Bu from Wuhan University School and Hospital of Stomatology, has published a comprehensive review entitled “Triaptosis and Cancer: Next Hope?” in the journal Research. This article systematically elaborates the triaptosis pathway from molecular mechanism to therapeutic application, detailing its signaling cascade, discussing the central role of oxidative stress homeostasis in cancer, and offering a forward-looking perspective on future directions—collectively underscoring the compelling potential of triaptosis as a novel anticancer strategy.

A research group led by Drs. Shusuke Tada and Takashi Tsuyama at the Department of Molecular Biology, Faculty of Pharmaceutical Sciences, Toho University, has demonstrated that overexpression of Cdc10-dependent transcript 1 (CDT1), a key regulator of DNA replication initiation, induces DNA damage and potentially results in genetic mutations. Although previous studies have linked CDT1 overexpression to cellular transformation and tumorigenesis, the underlying mechanism has remained unclear. The findings not only reveal the impact of CDT1 overexpression on DNA replication progression post initiation but also provide molecular insights into its role in cancer development.

Scientists have developed a new computational tool that maps multi-gene pathways more comprehensively than ever before.

The study uncovered a previously unknown protein pathway that, when blocked, kills blood cancer cells.

The discovery could lead to new therapies for patients with drug-resistant blood cancers.

According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.

Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.